Creo Medical Group (LON:CREO) Shares Down 4.2% – Here’s What Happened

Creo Medical Group PLC (LON:CREO) shares were down 4.2% on Wednesday . The stock traded as low as GBX 15.50 and last traded at GBX 15.80. Approximately 1,069,990 shares traded hands during trading, a decline of 1% from the average daily volume of 1,079,152 shares. The stock had previously closed at GBX 16.50.

Creo Medical Group Price Performance

The company has a debt-to-equity ratio of 29.96, a quick ratio of 2.19 and a current ratio of 3.24. The stock has a market capitalization of £65.17 million, a PE ratio of -15.80 and a beta of 0.86. The stock’s 50 day moving average is GBX 13 and its two-hundred day moving average is GBX 12.10.

Insider Activity at Creo Medical Group

In other news, insider Craig Jonathan Gulliford acquired 8,036 shares of Creo Medical Group stock in a transaction that occurred on Tuesday, January 13th. The stock was purchased at an average cost of GBX 11 per share, with a total value of £883.96. Also, insider Richard John Rees acquired 8,036 shares of the firm’s stock in a transaction on Tuesday, January 13th. The stock was purchased at an average price of GBX 11 per share, for a total transaction of £883.96. Company insiders own 4.11% of the company’s stock.

Creo Medical Group Company Profile

Creo Medical is a medical device company focused on the development and commercialisation of minimally invasive electrosurgical devices, bringing advanced energy to endoscopy.

The Company’s vision is to improve patient outcomes through the development and commercialisation of a suite of electrosurgical medical devices, each enabled by CROMA, powered by Kamaptive. The Group has developed the CROMA powered by Kamaptive full-spectrum adaptive technology to optimise surgical capability and patient outcomes.